NLRP3 and Parkinson disease: Indeed, outside of cancer, RRx-001, the most clinically advanced of the direct NLRP3 inhibitors, including MCC950, which is no longer in development, has received FDA Fast Track status (29) as a radioprotector to prevent/ameliorate severe oral mucositis based on the results of a randomized Phase 2 clinical trial called PREVLAR (30) and is also under preclinical study in Parkinson’s Disease and amyotrophic lateral sclerosis (ALS)/motor neuron disease with grants awarded from the Michael J. Fox Foundation (MJFF) and Fight MND, respectively.